The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Open accessAbstract
Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice deficient in the cannabinoid receptor CB1 tolerate inflammatory and excitotoxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614
Self-citationMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 2×
“…of the receptors, fatty acid endogenous ligands, such as anandamide and 2-arachidonoyl glycerol (2-AG), and a degradation system including a re-uptake mechanism and hydrolytic enzymes have been identi®ed (Devane et al., 1992; Deutsch and Chin, 1993; Mechoulam et al., 1995; Dinh et al., 2002).”
BackgroundInfluentialInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Without the use of tissue-speci®c CB1 conditional knockouts (Marsicano et al., 2002), it is probably not possible to completely exclude some in¯uence of cannabinoid inhibition of the immune response in the neurodegenerative process.”
MethodLock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 2×
“The cannabinoid system functions to regulate synaptic neurotransmission (Kreitzer and Regehr, 2001; Wilson and Nicoll, 2001) and tonically controls clinical signs such as spasticity and tremor that develop in chronic EAE (Baker et al., 2000, 2001).”
BackgroundAxonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 2×
“…Group, Institute of Neurology, University College London, Queen Square, London, UK Correspondence to: Dr David Baker, Institute of Neurology, University College London, 1 Wake®eld Street, London WC1N 1PJ, UK E-mail: d.baker@ion.ucl.ac.uk *These authors contributed equally to this work”
BackgroundRelapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Kreitzer, A. C., & Regehr, W. G. (2001) · Neuron · doi:10.1016/s0896-6273(01)00246-x · Cited by 875
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · cited 2×
“Cannabinoids also have anti-oxidant properties that could further limit damaging events during in¯ammation (Hampson et al., 1998; Howlett et al., 2002).”
BackgroundAn endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
Glutamate excitotoxicity in a model of multiple sclerosis
Pitt, D., Werner, P., & Raine, C. S. (2000) · Nature Medicine · doi:10.1038/71555 · Cited by 744
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Deutsch, D. G., & Chin, S. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90486-g · Cited by 702
Neuronal Death in the Hippocampus Is Promoted by Plasmin-Catalyzed Degradation of Laminin
Chen, Z.-L., & Strickland, S. (1997) · Cell · doi:10.1016/s0092-8674(00)80483-3 · Cited by 632
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
Twitchell, W., Brown, S., & Mackie, K. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.78.1.43 · Cited by 544
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Di Marzo, V., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 541
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 532
Self-citationEvidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability
De Stefano, N., Narayanan, S., Francis, G. S., Arnaoutelis, R., Tartaglia, M. C., Antel, J. P., Matthews, P. M., & Arnold, D. L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.1.65 · Cited by 505
Werner, P., Pitt, D., & Raine, C. S. (2001) · Annals of Neurology · doi:10.1002/ana.1077 · Cited by 486
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases.
Koprowski, H., Zheng, Y. M., Heber-Katz, E., Fraser, N., Rorke, L., Fu, Z. F., Hanlon, C., & Dietzschold, B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.3024 · Cited by 474
Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures
Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., & Greenberg, D. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02987.1999 · Cited by 468
Autoimmune encephalomyelitis ameliorated by AMPA antagonists
Smith, T., Groom, A., Zhu, B., & Turski, L. (2000) · Nature Medicine · doi:10.1038/71548 · Cited by 467
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 393
Endocannabinoids control spasticity in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0399fje · Cited by 378
Self-citationEvidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis
Filippi, M. (2003) · Brain · doi:10.1093/brain/awg038 · Cited by 371
The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis
Consroe, P., Musty, R., Rein, J., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 323
Electrically active axons degenerate when exposed to nitric oxide
Smith, K. J., Kapoor, R., Hall, S. M., & Davies, M. (2001) · Annals of Neurology · doi:10.1002/ana.96 · Cited by 320
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
Arévalo-Martı́n, Á., Vela, J. M., Molina-Holgado, E., Borrell, J., & Guaza, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02511.2003 · Cited by 314
Wujek, J. R., Bjartmar, C., Richer, E., Ransohoff, R. M., Yu, M., Tuohy, V. K., & Trapp, B. D. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.1.23 · Cited by 289
The longstanding MS lesion. A quantitative MRI and electron microscopic study
BARNES, D., MUNRO, P. M. G., YOUL, B. D., PRINEAS, J. W., & MCDONALD, W. I. (1991) · Brain · doi:10.1093/brain/114.3.1271 · Cited by 256
Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degeneration
Kapoor, R., Davies, M., Blaker, P. A., Hall, S. M., & Smith, K. J. (2003) · Annals of Neurology · doi:10.1002/ana.10443 · Cited by 252
The absolute configuration of δ1-tetrahydrocannabinol, the major active constituent of hashish.
Mechoulam, R., & Gaoni, Y. (1967) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)90646-4 · Cited by 231
Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice
Parmentier-Batteur, S., Jin, K., Mao, X. O., Xie, L., & Greenberg, D. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09771.2002 · Cited by 225
Anandamide, but not 2‐arachidonoylglycerol, accumulates during in vivo neurodegeneration
Hansen, H. H., Schmid, P. C., Bittigau, P., Lastres‐Becker, I., Berrendero, F., Manzanares, J., Ikonomidou, C., Schmid, H. H. O., Fernández‐Ruiz, J. J., & Hansen, H. S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00542.x · Cited by 215
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Killestein, J., Hoogervorst, E. L. J., Reif, M., Kalkers, N. F., van Loenen, A. C., Staats, P. G. M., Gorter, R. W., Uitdehaag, B. M. J., & Polman, C. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1404 · Cited by 209
Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis
Lyman, W. D., Sonett, J. R., Brosnan, C. F., Elkin, R., & Bornstein, M. B. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90075-1 · Cited by 200
Croxford, J. L., & Miller, S. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17652 · Cited by 196
Self-citationInduction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice
Baker, D., O'Neill, J. K., Gschmeissner, S. E., Wilcox, C. E., Butter, C., & Turk, J. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90019-j · Cited by 192
Self-citationSafety, tolerability, and efficacy of orally administered cannabinoids in MS
Russo, E. B. (2003) · Neurology · doi:10.1212/wnl.60.4.729-a · Cited by 184
Therapeutic Approaches in Multiple Sclerosis: Lessons from Failed and Interrupted Treatment Trials
Wiendl, H., & Hohlfeld, R. (2002) · BioDrugs · doi:10.2165/00063030-200216030-00003 · Cited by 183
Henry, D. J., & Chavkin, C. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11289-9 · Cited by 173
Reorganization of the Axon Membrane in Demyelinated Peripheral Nerve Fibers: Morphological Evidence
Foster, R. E., Whalen, C. C., & Waxman, S. G. (1980) · Science · doi:10.1126/science.6159685 · Cited by 139
Kalkers, N. F., Barkhof, F., Bergers, E., van Schijndel, R. A., & Polman, C. H. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms849xx · Cited by 136
Cannabinoids Inhibit the Formation of New Synapses between Hippocampal Neurons in Culture
Kim, D., & Thayer, S. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0004.2001 · Cited by 134
Suppression of experimetal autoimmune encephalomyelitis by cannabinoids
Wirguin, I., Mechoulam, R., Breuer, A., Schezen, E., Weidenfeld, J., & Brenner, T. (1994) · Immunopharmacology · doi:10.1016/0162-3109(94)90056-6 · Cited by 130
Black, J. A., Dib‐Hajj, S. D., Baker, D., Newcombe, J., Cuzner, M. L., & Waxman, S. G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11598 · Cited by 127
Self-citationBrooks, J. W., Pryce, G., Bisogno, T., Jaggar, S., Hankey, D. J. R., Brown, P., Bridges, D., Ledent, C. A., Bifulco, M., Rice, A. S. C., et al. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01369-9 · Cited by 85
Self-citationNeuroprotection of axons with phenytoin in experimental allergic encephalomyelitis
Lo, A., Black, J. A., & Waxman, S. G. (2002) · Neuroreport · doi:10.1097/00001756-200210280-00015 · Cited by 83
Achiron, A., Miron, S., Lavie, V., Margalit, R., & Biegon, A. R. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00149-6 · Cited by 77
Novel, Not Adenylyl Cyclase-Coupled Cannabinoid Binding Site in Cerebellum of Mice
Monory, K., Tzavara, E. T., Lexime, J., Ledent, C. A., Parmentier, M., Borsodi, A. D., & Hanoune, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6635 · Cited by 75
Self-citationMK-801 Limits Neurovascular Dysfunction during Experimental Allergic Encephalomyelitis
Bolton, C., & Paul, C. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36794-1 · Cited by 71
Stereochemistry of the π-route to 2,4-disubstituted adamantanes
Sasaki, T., Eguchi, S., & Toru, T. (1971) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)96639-0 · Cited by 67
Pocock, J. M., & Nicholls, D. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70020806.x · Cited by 54
Self-citationA Role for Caspase-1 and -3 in the Pathology of Experimental Allergic Encephalomyelitis
Ahmed, Z., Doward, A. I., Pryce, G., Taylor, D. L., Pocock, J. M., Leonard, J. P., Baker, D., & Cuzner, M. L. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64436-7 · Cited by 53
Self-citationEvans, G. J., & Pocock, J. M. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00427.x · Cited by 40
Self-citationO'Neill, J. K., Baker, D., DAVISON, A. N., Maggon, K. K., JAFFEE, B. D., & Turk, J. L. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90090-8 · Cited by 34
Self-citationSelley, D. E., Rorrer, W. K., Breivogel, C. S., Zimmer, A. M., Zimmer, A., Martin, B. R., & Sim‐Selley, L. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00308.x · Cited by 31
Hankey, D. J. R., Lightman, S., & Baker, D. (2001) · Experimental Eye Research · doi:10.1006/exer.2000.0957 · Cited by 28
Self-citationKordower (1999) · doi:10.1002/1531-8249(199909)46:3
(2000) · doi:10.1002/1531-8249(200012)48:6
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Lyman et al. (1989) examined the effects of parenteral THC in experimental autoimmune encephalomyelitis (EAE) in rats, a laboratory model of MS. THC treatment not only reduced CNS inflammation and improved neurological outcome but also improved survival compared with placebo.”
BackgroundInfluentialExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Inflammation in neurodegenerative diseases—An update
Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., & van Noort, J. M. (2014) · Immunology · doi:10.1111/imm.12233 · Cited by 550
Self-citation
Metadata
- Authors
- Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., Cuzner, M. L., & Baker, D.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-10
- Volume
- 126
- Issue
- 10
- Pages
- 2191-2202
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2165031951
- Cited by
- 342
- References
- 70
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.